| Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer A de Gramont, A Figer, M Seymour, M Homerin, A Hmissi, J Cassidy, ... Journal of clinical oncology 18 (16), 2938-2947, 2000 | 5061 | 2000 |
| First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer BJ Solomon, T Mok, DW Kim, YL Wu, K Nakagawa, T Mekhail, E Felip, ... New England Journal of Medicine 371 (23), 2167-2177, 2014 | 3551 | 2014 |
| Fluorouracil leucovorin and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer C Bokemeyer, I Bondarenko, A Makhson, JT Hartmann, J Aparicio, ... Journal of clinical oncology 27 (5), 663-671, 2009 | 2170 | 2009 |
| Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma GV Long, D Stroyakovskiy, H Gogas, E Levchenko, F de Braud, J Larkin, ... New England Journal of Medicine 371 (20), 1877-1888, 2014 | 1974 | 2014 |
| Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial GV Long, D Stroyakovskiy, H Gogas, E Levchenko, F De Braud, J Larkin, ... The Lancet 386 (9992), 444-451, 2015 | 1535 | 2015 |
| Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial SJ Antonia, JA López-Martin, J Bendell, PA Ott, M Taylor, JP Eder, ... The Lancet Oncology 17 (7), 883-895, 2016 | 1291 | 2016 |
| Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study C Bokemeyer, I Bondarenko, JT Hartmann, F De Braud, G Schuch, ... Annals of oncology 22 (7), 1535-1546, 2011 | 1004 | 2011 |
| Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer DG Haller, J Tabernero, J Maroun, F de Braud, T Price, E Van Cutsem, ... J Clin Oncol 29 (11), 1465-1471, 2011 | 934 | 2011 |
| Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 and STARTRK-1) A Drilon, S Siena, SHI Ou, M Patel, MJ Ahn, J Lee, TM Bauer, AF Farago, ... Cancer discovery 7 (4), 400-409, 2017 | 770 | 2017 |
| Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial P Sharma, MK Callahan, P Bono, J Kim, P Spiliopoulou, E Calvo, ... The lancet oncology 17 (11), 1590-1598, 2016 | 727 | 2016 |
| Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study GV Long, KT Flaherty, D Stroyakovskiy, H Gogas, E Levchenko, ... Annals of Oncology 28 (7), 1631-1639, 2017 | 715 | 2017 |
| Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas Y Jiao, TM Pawlik, RA Anders, FM Selaru, MM Streppel, DJ Lucas, ... Nature genetics 45 (12), 1470-1473, 2013 | 689 | 2013 |
| Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer A Drilon, GR Oxnard, DSW Tan, HHF Loong, M Johnson, J Gainor, ... New England Journal of Medicine 383 (9), 813-824, 2020 | 669 | 2020 |
| Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis F Pietrantonio, F Petrelli, A Coinu, M Di Bartolomeo, K Borgonovo, ... European journal of cancer 51 (5), 587-594, 2015 | 590 | 2015 |
| Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels M Colleoni, A Rocca, MT Sandri, L Zorzino, G Masci, F Nole, G Peruzzotti, ... Annals of Oncology 13 (1), 73-80, 2002 | 583 | 2002 |
| CheckMate-032 study: efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer YY Janjigian, J Bendell, E Calvo, JW Kim, PA Ascierto, P Sharma, PA Ott, ... Journal of Clinical Oncology 36 (28), 2836, 2018 | 573 | 2018 |
| Gastric cancer V Catalano, R Labianca, GD Beretta, G Gatta, F De Braud, E Van Cutsem Critical reviews in oncology/hematology 71 (2), 127-164, 2009 | 568 | 2009 |
| Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth G Germano, S Lamba, G Rospo, L Barault, A Magrì, F Maione, M Russo, ... Nature 552 (7683), 116-120, 2017 | 559 | 2017 |
| Colon cancer R Labianca, GD Beretta, B Kildani, L Milesi, F Merlin, S Mosconi, ... Critical reviews in oncology/hematology 74 (2), 106-133, 2010 | 520 | 2010 |
| Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind … SB Kim, R Dent, SA Im, M Espié, S Blau, AR Tan, SJ Isakoff, M Oliveira, ... The Lancet Oncology 18 (10), 1360-1372, 2017 | 484 | 2017 |
